Naidoo P, Bouharati C, Rambiritch V, Karamchand S, Tafuto BA, Leisegang RF. Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide-1 receptor agonists: A systematic review. World J Meta-Anal 2021; 9(3): 297-308 [DOI: 10.13105/wjma.v9.i3.297]
Corresponding Author of This Article
Poobalan Naidoo, BPharm, MBChB, MSc, Academic Research, Doctor, Department of Nephrology, Inkosi Albert Luthuli Central Hospital, 800 Vusi Mzimela Rd, Durban 4092, KwaZulu-Natal, South Africa. poobalan1naidoo@yahoo.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Meta-Anal. Jun 28, 2021; 9(3): 297-308 Published online Jun 28, 2021. doi: 10.13105/wjma.v9.i3.297
Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide-1 receptor agonists: A systematic review
Poobalan Naidoo, Celia Bouharati, Virendra Rambiritch, Sumanth Karamchand, Barbara A Tafuto, Rory F Leisegang
Poobalan Naidoo, Department of Nephrology, Inkosi Albert Luthuli Central Hospital, Durban 4092, KwaZulu-Natal, South Africa
Celia Bouharati, Department of Medical Research, Independent Researcher, Paris 75000, France
Virendra Rambiritch, Department of Pharmacology, University of KwaZulu-Natal, Durban 3629, KwaZulu-Natal, South Africa
Sumanth Karamchand, Department of Internal Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town 7600, South Africa
Barbara A Tafuto, Department of Health Informatics, Rutgers University, Piscataway, NJ 08854, United States
Rory F Leisegang, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala 75236, Sweden
Author contributions: Naidoo P and Tafuto BA conceived the manuscript; Leisegang RF, Rambiritch V, Karamchand S and Bouharati C reviewed all drafts and added critical comment and content; All authors read the final manuscript, consented to submission and take full responsibility for the content.
Conflict-of-interest statement: No conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Poobalan Naidoo, BPharm, MBChB, MSc, Academic Research, Doctor, Department of Nephrology, Inkosi Albert Luthuli Central Hospital, 800 Vusi Mzimela Rd, Durban 4092, KwaZulu-Natal, South Africa. poobalan1naidoo@yahoo.com
Received: March 27, 2021 Peer-review started: March 27, 2021 First decision: May 12, 2021 Revised: June 5, 2021 Accepted: July 2, 2021 Article in press: July 2, 2021 Published online: June 28, 2021 Processing time: 107 Days and 3.6 Hours
ARTICLE HIGHLIGHTS
Research background
Fixed ratio combinations of insulin and glucagon-like peptide-1 analogues are novel therapy for the management of patients with type 2 diabetes mellitus.
Research motivation
There is minimal data comparing the fixed ratio combinations of iGlarlixi and IDegLira.
Research objectives
We aimed to compare the glucose lowering effect of iGlarLixi vs IDegLira.
Research methods
We used a Population, Intervention, Comparison, Outcome (PICO) question for the primary analysis.
Research results
Both iGlarLixi and IDegLira effectively reduce glycated haemoglobin when compared to insulin glargine U100. However, using indirect comparisons, IDegLira had a greater HbA1c reducing ability (0.6% vs 0.3%).
Research conclusions
Both iGlarLixi and IDegLira effectively reduce glycated haemoglobin.
Research perspectives
Head to head studies between iGlarlixi and IDegLira are required to determine if there are clinically relevant differences between the two aforementioned fixed ratio combinations.
